检索结果-南通市图书馆

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

麻醉信息管理系统的使用：一项实践指南

麻醉与镇痛 2010年第2期6卷 90-99页

作者： Stanley Muravchick, MD, phd James E. Caldwell, MB, ChB Richard H. Epstein, MD Maria Galati, MBA Warren J. Levy, MD Michael O'Reilly, MD Jeffrey S. Plagenhoef, MD Mohamed Rehman, MD david L. Reich, MD Michael M. Vigoda, MD, MBA 任思宏(译) 刘兴奎(校) 喻田(校) Department of Anesthesiology and Critical Care University of Pennsylvania School of Medidne Philadelphia Pennsylvania Department of Anesthesia and Perioperative Care University of California San Frandsoo California Department of Anesthesiology Thomas Jefferson University School of Medicine Philadelphia Pennsylvania Deparunent of Anesthesiology Mount Sinai School of Medidne New York New York ii Department of Anesthesiology University of Michigan Ann Arbor Michigan Department of Anesthesiology Southeast Alabama Medical Center Dothan Alabama Department of Anesthesiology and Critical Care Children's Hospital of Philadelphia Pennsylvania Department of Anesthesiology University of Miami School of Medidne Miami Florida 不详

麻醉信息管理系（AnesthesiaInformationMangementsysterns，AIMS）显示和储存围手术期的生理学数据和患者信息。虽然目前应用有限，但是在提高患者安全、改进临床效果和质量、简便收费和明细医疗费用、规范执行以及研究麻醉转归等方面... 详细信息

麻醉信息管理系（AnesthesiaInformationMangementsysterns，AIMS）显示和储存围手术期的生理学数据和患者信息。虽然目前应用有限，但是在提高患者安全、改进临床效果和质量、简便收费和明细医疗费用、规范执行以及研究麻醉转归等方面都有巨大的优势。虽然关于AIMS选择、安装和应用的程序和注意事项比较复杂，但是这些都可以通过不断摸索而明确。本文总结介绍了AIMS成功使用的基本要素，包括产品评估、信息技术需求评价、资源获得、领导的作用以及培训等。

关键词：麻醉信息管理系统实践指南 AIMS 围手术期临床效果医疗费用产品评估需求评价

围手术期输注红细胞可降低心脏手术术后远期存活率

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

麻醉与镇痛 2010年第5期6卷 81-88页

作者： Stephen D. Surgenor, MD Robert S. Kramer, MD Elaine M. Olmstead, BA Cathy S. Ross, MS Frank W. Sellke, MD Donald S. Likosky, phd Charles A. S. Martin, MBBS Robert E. Helm, Jr., mD Bruce J. Leavitt, MD Jeremy R. Morton, MD david C. Charlesworth, MD Robert A. Clough, MD Felix Hernandez, MD Carmine Frumiento, MD Arnold Benak, CCP Christian DioData, CCP Gerald T. O'Connor, phd, DSc 周全红(译) 江伟(校) Dartmouth-Hitchcock Medical Center Lebanon New Hampshire Maine Medical Center Portland Maine Dartmouth Medical School Hanover New Hampshire Beth Israel Deaconess Medical Center Boston Massachusetts Portsmouth Regional Hospital Portsmouth New Hampshire Fletcher Allen Health Care Burlington Vermont New England Heart Institute Catholic Medical Center Manchester New Hampshire Eastern Maine Medical Center Bangor Maine Central Maine Medical Center Lewiston Maine Concord Hospital Concord New Hampshire The Dartmouth Institute for Health Policy and Clinical Practice Dartmouth College Lebanon New Hampshire 不详

背景输注红细胞（RBC）与心脏手术后死亡率升高有关。我们分析了在住院期间接受了1或2个单位RBC输注的心脏手术患者的长期生存情况。方法将2001年至2004年期间9079例，在新英格兰北部地区8个医疗中心中接受了冠状动脉旁路移植术、瓣膜... 详细信息

背景输注红细胞（RBC）与心脏手术后死亡率升高有关。我们分析了在住院期间接受了1或2个单位RBC输注的心脏手术患者的长期生存情况。方法将2001年至2004年期间9079例，在新英格兰北部地区8个医疗中心中接受了冠状动脉旁路移植术、瓣膜手术或同时进行了冠状动脉旁路移植术和瓣膜手术的患者纳入本研究。研究将纳入地区与2006年6月30日社会保障署死亡档案确定的死亡率进行概率性配对。调整的风险比采用Cox比例风险和倾向评分法进行计算。结果36％的患者（n=3254）接受过1或2个单位的RBC。43％的RBCs是在手术中被输注的，分别有56％和1％的RBCs是在手术后和手术前输注的。输血的患者更可能是贫血、高龄、体表面积小、女性和同时患多种疾病的患者。那些在心脏手术住院期间接受了1或2个单位RBCs的患者的存活率显著低于未接受过RBCs的患者（P〈0．001）。调整了患者和疾病特征之后，接受1或2个单位RBCs仍使远期死亡风险提高16％（调整的风险比=1．16，95％CI：1．01—1．34，P=0．035）。结论输注1或2个单位的RBCs可使心脏手术术后存活率降低的风险提高16％。

关键词：术后死亡率心脏手术远期存活率红细胞输注围手术期冠状动脉旁路移植术 RBCs

Genome mapping of postzygotic hybrid necrosis in an interspecific pear population

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Horticulture Research 2016年第1期3卷 326-337页

作者： Sara Montanari Lester Brewer Robert Lamberts Riccardo Velasco Mickael Malnoy Laure Perchepied Philippe Guérif Charles-Eric Durel Vincent G M Bus Susan E Gardiner david Chagné Research and Innovation Centre Fondazione Edmund MachVia Mach 1San Michele all’Adige38010TNItaly The New Zealand Institute for Plant&Food Research Limited Palmerston North Research CentrePalmerston NorthNew Zealand Institut de Recherche en Horticulture et Semences-UMR1345 Institut National de la Recherche Agronomique(INRA)SFR 4207 Quasav42 rue Georges MorelBeaucouzéF-49071France The New Zealand Institute for Plant&Food Research Limited Motueka Research CentreMotuekaNew Zealand Institut de Recherche en Horticulture et Semences-UMR1345 Universitéd’AngersAngersF-49045France The New Zealand Institute for Plant&Food Research Limited Hawke’s Bay Research CentreHavelock NorthNew Zealand

Deleterious epistatic interactions in plant inter-and intraspecific hybrids can cause a phenomenon known as hybrid necrosis,characterized by a typical seedling phenotype whose main distinguishing features are dwarfism,tissue necrosis and in some cases *** of the chromosome regions associated with this type of incompatibility is important not only to increase our understanding of the evolutionary diversification that led to speciation but also for breeding *** of molecular markers linked to the lethal genes will allow breeders to avoid incompatible inbred combinations that could affect the expression of important agronomic tratis co-segregating with these *** hybrid necrosis has been reported in several plant taxa,including Rosaceae species,this phenomenon has not been described previously in *** the interspecific pear population resulting from a cross between PEAR3(Pyrus bretschneideri×Pyrus communis)and‘Moonglow’(***),we observed two types of hybrid necrosis,expressed at different stages of plant *** a combination of previously mapped and newly developed genetic markers,we identified three chromosome regions associated with these two types of lethality,which were genetically *** type resulted from a negative epistatic interaction between a locus on linkage group 5(LG5)of PEAR3 and a locus on LG1 of‘Moonglow’,while the second type was due to a gene that maps to LG2 of PEAR3 and which either acts alone or more probably interacts with another gene of unknown location inherited from‘Moonglow’.

关键词： breeding seedling dwarf

急性心肌梗死后循证药物治疗依从性与远期死亡率的关系

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

美国医学会杂志（中文版） 2008年第3期27卷 191-191页

作者： Jeppe N. Rasmussen, MD Alice Chong, BSc david A. Alter, MD, phd 纪璟峰(译) 赵秀丽(校)

背景：目前尚不清楚患者服药依从性可在多大程度上影响其生存率，这部分是由于“健康依从者”的行为可能较药物疗效更能影响其生存率。目的：研究急性心肌梗死（acute myocardial infarction，AMI）患者服药依从性与死亡率的关系。

关键词：药物治疗依从性急性心肌梗死后远期死亡率服药依从性循证药物疗效生存率

Cryo-EM structure of the plant 26S proteasome

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Plant Communications 2022年第3期3卷 116-126页

作者： Susanne Kandolf Irina Grishkovskaya Katarina Belacic Derek L.Bolhuis Sascha Amann Brent Foster Richard Imre Karl Mechtler Alexander Schleiffer Hemant D.Tagare Ellen D.Zhong Anton Meinhart Nicholas G.Brown david Haselbach Research Institute of Molecular Pathology(IMP) Vienna BioCenter(VBC)Campus-Vienna-BioCenter 11030 ViennaAustria Department of Radiology and Biomedical Imaging Yale UniversityNew HavenCT 06510USA Department of Pharmacology and Lineberger Comprehensive Cancer Center University of North Carolina School of MedicineChapel HillNC 27599USA Computer Science and Artificial Intelligence Laboratory Massachusetts Institute of TechnologyCambridgeMA 02139USA Vienna BioCenter phd Program Doctoral School of the University at Vienna and Medical University of ViennaVienna BioCenter(VBC)ViennaAustria Institute of Physical Chemistry University of FreiburgAlbertstraße 21Freiburg 79104Germany CIBSS Centre for Integrative Biological Signalling Studies University of FreiburgFreiburgGermany

Targeted proteolysis is a hallmark of *** is especially important in long-lived cells that can be found in higher eukaryotes,like *** task is mainly fulfilled by the ubiquitin–proteasome ***,proteolysis by the 26S proteasome is vital to development,immunity,and cell *** the yeast and animal proteasomes are well characterized,there is only limited information on the plant *** determined the first plant 26S proteasome structure from Spinacia oleracea by single-particle electron cryogenic microscopy at an overall resolution of 3.3 A°.We found an almost identical overall architecture of the spinach proteasome compared with the known structures from mammals and ***,we noticed a structural difference in the proteolytic active b1 ***,we uncovered an unseen compression state by characterizing the proteasome’s conformational *** suspect that this new conformation of the 20S core protease,in correlation with a partial opening of the unoccupied gate,may contribute to peptide release after *** data provide a structural basis for the plant proteasome,which is crucial for further studies.

关键词： 26S proteasome spinach UPS cryo-EM conformational landscape

Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering Drugs

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Incidence of Hospitalized Rhabdomyolysis in Patients Treated...

透皮东莨菪碱贴剂联合昂丹司琼对比单独应用昂丹司琼用于预防门诊手术后恶心呕吐的一项随机双盲多中心研究

中成药上市后药物流行病学评价培训会议

作者： david J.Graham Judy A.Staffa Deborah Shatin Susan E.Andrade Stephanie D.Schech Lois La Grenade Jerry H.Gurwitz K.Arnold Chan Michael J.Goodman Richard Platt Office of Drug Safety Center for Drug Evaluation and ResearchFood and Drug AdministrationRockvilleMd MDMPH Office of Drug Safety Center for Drug Evaluation and ResearchFood and Drug AdministrationRockvilleMd PhD Center for Health Care Policy and Evaluation Eden PrairieMinn PhD Meyers Primary Care Institute Fallon Foundation and the University of Massachusetts Medical SchoolWorcester ScD Center for Health Care Policy and Evaluation Eden PrairieMinn MPH Meyers Primary Care Institute Fallon Foundation and the University of Massachusetts Medical SchoolWorcester MD School of Public Health Channing Laboratory Brigham and Women's Hospital and Harvard Medical School Department of EpidemiologyHarvard MDScD Boston Mass Channing Laboratory Brigham and Women's Hospital and Harvard Medical School Department of Ambulatory Care and Prevention Harvard Pilgrim Health Care and Harvard Medical School MDMSc

Context Lipid-lowering agents are widely prescribed in the United *** estimates of rhabdomyolysis risk with various lipid-lowering agents are not available. Objective To estimate the incidence of rhabdomyolysis in patients treated with different statins and fibrates,alone and in combination,in the ambulatory setting. Design,Setting,and Patients Drug-specific inception cohorts of statin and fibrate users were established using claims data from 11 managed care health plans across the United *** with at least 180 days of prior health plan enrollment were entered into the cohorts between January 1,1998,and June 30,***-time was classified as monotherapy or combined statin-fibrate therapy. Main Outcome Measure Incidence rates of rhabdomyolysis per 10000 person-years of treatment,number needed to treat,and relative risk of rhabdomyolysis. Results In 252460 patients treated with lipid-lowering agents,24 cases of hospitalized rhabdomyolysis occurred during *** incidence per 10000 person-years for monotherapy with atorvastatin,pravastatin,or simvastatin was 0.44(95% confidence interval[CI],0.20-0.84);for cerivastatin,5.34(95%CI,1.46-13.68);and for fibrate,2.82(95%CI,0.58-8.24).By comparison,the incidence during unexposed person-time was 0(95%CI,0-0.48;P=.056).The incidence increased to 5.98 (95%CI,0.72-216.0) for combined therapy of atorvastatin,pravastatin,or simvastatin with a fibrate,and to 1035(95%CI,389-2117) for combined cerivastatin-fibrate *** year of therapy,the number needed to treat to observe 1 case of rhabdomyolysis was 22727 for statin monotherapy,484 for older patients with diabetes mellitus who were treated with both a statin and fibrate,and ranged from 9.7 to 12.7 for patients who were treated with cerivastatin plus fibrate. Conclusions Rhabdomyolysis risk was similar and low for monotherapy with atorvastatin, pravastatin,and simvastatin;combined statin-fibrate use increased risk,especially in older patients w

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

麻醉与镇痛 2010年第5期6卷 34-40页

作者： Tong J. Gan, MD Ashish C. Sinha, MD, phd Anthony L. Kovac, MD R. Kevin Jones, MD, CPI Stephen A.Cohen,MD,MBA Jean P. Battildaa, MS Jonathan S. Deutsch, MD Joseph V. Pergolizzi, Jr., MD] TDS Study Group 王琦(译) 李文志(校) Department of Anesthesiology Duke University Medical Center Durham North Carolina University of Pennsylvania Philadelphia Pennsylvania ＊University of Kansas Medical Center Kansas City Kansas Accurate Clinical Trials Inc./Saddleback Memorial Medical Center Laguna Hills California Beth Israel Deaconess Medical Center Boston Massachusetts Baxter Healthcare Corporation New Providence New Jersey Departrnent of Medicine Johns Hopkins University School of Medicine Baltimore Maryland The TDS Study Group consists of the following members: Gregory H. Adkisson (St. Agnes Healthcare Inc. Baltimore MD St. Agnes Healthcare Inc. Clinical Research Center Baltimore MD) I(eith Candiotti(University of Miami School of Medidne Jackson Health Systems Miami FL) Stephen & Cohen(Beth Israel Deaconess Medical Center Boston MA) Nell R. Connelly(Baystate Medical Center Springfield MA) Patricia L. Dalby(Magee Women's Hospital of UPMC Pittsburgh PA) Robert D'Angelo(Forsyth Medical Center Winston-Salem NC) Albert R. Davis(Loyola University Medical Center Chicago IL) David 1L Drover (Stanford Hospital and Clinics Stanford CA) Tong J. Gan Fernando Altermatt Dianne Scott(Duke University Medical Center Durham NC Duke Health Raleigh Hospital Raleigh NC and Duke Center for Aesthetic Services Durham NC) Joseph S. Gimbel(AZ Research Center John C. Lincoln Hospital North Mountain and John C. Lincoln Hospital Deer Valley Phoenix AZ)R.Kevin Jones (Saddleback Memorial Medical Center Laguna Hills CA) Anthony L. Kovac(University of Kansas Medical Center Kansas City Kansas KS) John B. Leslie(Mayo Clinic Hospital Phoenix AZ) Roberta McI(inney Jr. (Trinity Clinic North Park Mother Frances Hospital and Tyler Square Tyler TX) Tricia A. Meyer ( Scott and White Hospital Temple TX ) Joseph Pergolizzi (Physicians Day Surgery Center Naples FL) Beverly tC Philip (Brigham and Women's Hospital Boston MA) Martin I. Redmond(State University of New York at Stony Brook Ambulatory Surgica

背景手术后恶心、呕吐（PONV）是门诊手术常见的并发症。本试验目的是观察透皮东莨菪碱贴剂（TDS）联合静脉注射昂丹司琼（OND）对门诊患者PONV的疗效是否优于单独应用昂丹司琼。方法此项随机双盲多中心的临床试验纳入了620例接受门诊... 详细信息

背景手术后恶心、呕吐（PONV）是门诊手术常见的并发症。本试验目的是观察透皮东莨菪碱贴剂（TDS）联合静脉注射昂丹司琼（OND）对门诊患者PONV的疗效是否优于单独应用昂丹司琼。方法此项随机双盲多中心的临床试验纳入了620例接受门诊腹腔镜或隆胸手术的PONV高危女性患者，进入手术室前2小时分别给患者贴上TDS贴剂或外观相同的空白贴剂。在全麻诱导前2—5分钟给所有患者静脉注射OND4mg。手术后24~48小时评估止吐是否完善（彻底止吐标准为无呕吐或干呕，且没有追加止吐药）。同时记录发生呕吐、干呕、恶心以及追加止吐药的患者比例，记录手术后首次发生PONV的时间及离院时间，记录呕吐、干呕、恶心的发作次数与严重程度及患者对于止吐治疗的满意度。结果TDS＋OND组与OND组相比，手术后24小时恶心、呕吐的发生率显著降低，但手术后48小时两者差异无显著性。TDS＋OND组没有呕吐、干呕且未追加过止吐药的患者占48％，而OND组占39％（P〈0．02）。TDS＋OND组的彻底止吐（无恶心、呕吐或干呕，且未追加止吐药）率显著高于OND组（分别为35％和25％，P〈0．01）。TDS＋OND组手术后首次发生恶心、呕吐、干呕及追加止吐药的时间明显晚于OND组（P〈0．05）。前者不良反应的总发生率也低于后者（分别为36．7％和49％，P〈0．01）。结论与单独应用OND相比。TDS＋OND能更大程度地减少PONV，主要是通过减少不良反应而获得。

关键词：手术后恶心呕吐东莨菪碱贴剂多中心研究昂丹司琼门诊手术随机双盲应用单独